Single speciality-focused healthcare provider Asia Healthcare Holdings (AHH)-owned Nova IVF Fertility has acquired Kerala-based Craft Fertility (Centre for Research in Assisted Reproduction and Fetal Therapy) for an undisclosed amount.

The collaboration will help to see the launch of 10 new centres over the next 3–5 years, said Vishal Bali, Executive Chairman, Asia Healthcare Holdings (AHH).

Located at Kodungallur near Kochi, Craft Fertility is one of the oldest fertility clinics in India, with over three decades of history and over 55,000 babies born at the Centre. It is headed by Dr. C. Mohamed Ashraf, Chairman & Medical Director, having over four decades of experience.

''This is not just an entry for Nova in the state of Kerala, but access to 4 decades of transformative clinical practices in reproductive medicine. The science of reproductive medicine is advancing at a very fast pace globally. The strong clinical and patient-centric approach followed by both enterprises promises to bring more advancements to fertility & IVF care to patients in the country,” said Bali.

Nova IVF Fertility is India’s leading and fastest-growing chain of fertility and IVF centres. It has enabled over 100,000 clinical pregnancies through its advanced reproductive technologies and has a footprint spanning 120 centres across 70 cities.

''As the fastest-growing IVF chain in the country, Nova is the right partner to help us scale quality fertility care into tier 2 and tier 3 regions of Kerala'', said Dr C. Mohamed Ashraf. This partnership comes at a critical juncture as Kerala's fertility rate has dropped to approximately 1.35–1.7 children per woman, well below the replacement level of 2.1, he added.

India currently performs 2.5–3 lakh IVF cycles annually. Over the past decade, the science of IVF in India has evolved significantly, moving from a niche treatment to a more widely accessible and technology-driven solution for infertility.

Advances in reproductive medicine, including improved embryo culture techniques, vitrification (egg and embryo freezing), preimplantation genetic testing (PGT), and the integration of AI-led embryo selection, have enabled improved success rates. Today, fertility care is increasingly personalised, with protocols tailored to individual patient profiles, leading to better clinical outcomes.

Backed by global investment giants GIC & TPG, AHH has a strong portfolio of leading healthcare brands across oncology (Cancer Treatment Services India exited in 2019), women and childcare (Motherhood Hospitals), fertility & reproductive medicine (Nova IVF Fertility), and urology & nephrology (Asian Institute of Nephrology and Urology – AINU).